Latest News and Press Releases

ACH-5228 delivers near complete and sustained inhibition of the complement alternative pathway Twice-daily oral administration to move forward in Phase 2 trials Investigational New Drug (IND)...

BLUE BELL, Pa., June 13, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...

BLUE BELL, Pa., June 10, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...

- ACH-4471 increased hemoglobin and nearly eliminated the need for transfusions in patients with PNH being treated with C5 inhibitor, eculizumab - BLUE BELL, Pa., May 17, 2019 (GLOBE NEWSWIRE) --...

BLUE BELL, Pa., May 14, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) ), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...

- PNH combo Phase 2 trial interim data to be presented May 17, 2019 -- C3G Phase 2 trials 24 patients enrolled as of May 2019 - - Next-generation ACH-5228 planned U.S. IND submission Q4:2019 -- Cash...

- Enrolled 23 patients in ACH-4471 Phase 2 C3G six and 12-month clinical trials -- Targeting end-of-Phase 2 meeting with FDA in fourth quarter of 2019 - BLUE BELL, Pa., April 03, 2019 (GLOBE...

- Completed enrollment in ACH-4471 Phase 2 PNH trial in combination with eculizumab -- Interim data to be released in May 2019 - - Targeting FDA end-of-Phase 2 meeting in second half of 2019 - BLUE...

BLUE BELL, Pa., March 08, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...

- Phase 2 trial enrollment on schedule in PNH combo, interim data expected in Q2:2019 -- Phase 2 trial enrollment on schedule in C3G, 24 sites recruiting -- Next-generation factor D inhibitor ACH-5228...